DealBook: Glaxo Said to Be Looking to Replace Human Genome's Board

NEW YORK (Reuters) - GlaxoSmithKline Plc has lined up

NEW YORK/LONDON (Reuters) - Gla

The British drug maker GlaxoSmithKline has changed the terms of its proposed takeover offer for Human Genome Sciences in response to the poison pill adopted by the biotechnology company.

LONDON (Reuters) - GlaxoSmithKline said it wou

By Rx Stocks:Reuters announced late Friday July 6, 2012 that an unnamed source said Celgene (CELG) may

NEW YORK/LONDON (Reuters) - GlaxoSmithKline Plc plans to launch a campaign to replace the entire board of Human Genome Sciences Inc with its own nominees, stepping up its $2.6 billion hostile bid for the U.S. biotech company, sources familiar with the situation said on Wednesday. GSK intends to initiate a consent solicitation process, which could come in the next few weeks, the sources said. Human Genome has started reaching out to executives in the pharmaceutical industry as well as finance and governance experts to nominate as candidates for Human Genome's board, the sources said. ...

NEW YORK/LONDON (

HGSI – Human Genome Sciences, Inc. – Shares in biotechnology company Human Genome Sciences are down 3.95% this afternoon at $25.23 as of 3:15 pm, but one options trader populating the December contract today is positioning for the stock to rebound ahead of a key FDA decision on its lupus drug treatment, Benlysta.